Genotyping News and Research

RSS

Study demonstrates new test for early diagnosis of Turner syndrome

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) has demonstrated a novel and accurate test for early diagnosis of Turner syndrome. Turner syndrome affects one in 1,500 to 2,000 female live births and early diagnosis allows for the timely management of short stature and co-morbid conditions including cardiac and renal problems.

9 Dec 2010

SaneVax Team congratulates Senator for examining NCI ethical questions

In a letter addressed to U.S. Senator Charles Grassley, the SaneVax Team congratulated the senator on his recent efforts to examine ethical questions raised by National Cancer Institute (NCI) employees accepting extensive travel sponsored by private companies and identified two senior NCI scientists who knowingly promote unreliable human papillomavirus (HPV) tests for patient care, and the development/monitoring of genotype-specific HPV vaccines to promote an unproven virology-based cervical cancer prevention business agenda.

29 Nov 2010

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today

19 Nov 2010

Study finds Hispanic children are susceptible to develop fatty liver disease

Two studies from the Childhood Obesity Research Center at the Keck School of Medicine of the University of Southern California (USC) have found evidence that Hispanic children and adolescents are genetically predisposed to developing fatty liver disease a condition that can lead to cirrhosis, cardiovascular disease and diabetes.

18 Nov 2010

Rheonix receives U.S patent for microfluidic device

Rheonix, Inc., developer of the Rheonix CARD system to provide multiplexed endpoint analysis for a wide breadth of diagnostic applications, announced that on November 16, 2010 the U.S. Patent and Trademark Office issued Patent Number 7,832,429 "Microfluidic Pump and Valve Structures and Fabrication Method" to the Company.

18 Nov 2010

New pharmacogenetic test enables a personalized medicine approach

Luminex Corporation, today announced that it has commercially launched its first pharmacogenetic test, the xTAG CYP2D6 Kit, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

From Luminex 17 Nov 2010

S.A.N.E. Vax calls for federal approval of reliable HPV genotyping test in cervical cancer prevention programs

In a letter addressed to Dr. Harold E. Varmus, director of the NCI, and Dr. Margaret Hamburg, FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc., requested that these two federal agencies recommend a reliable human papillomavirus (HPV) genotyping test to support the national virology-based cervical cancer prevention program for patient care. Erickson stated: "The NCI knows reliable HPV genotyping is based on using a PCR system with short target sequencing."

9 Nov 2010

Affymetrix to contribute genotyping data to 1000 Genomes Project

Affymetrix, Inc. today announced that it will contribute genotyping data for a large set of validated rare and common genomic variants to the 1000 Genomes Project. This powerful data consists of genotyping information from more than 2 million single nucleotide polymorphisms (SNPs), and insertions/deletions (indels), many of which were not previously available from any source.

4 Nov 2010

Illumina, Expression Analysis support Cancer GWAS and Data Analysis Grant program

Expression Analysis today announced that it and Illumina, Inc. are jointly funding a Cancer GWAS (Genome-Wide Association Study) and Data Analysis Grant program to support cutting-edge projects that show promise in identifying genetic elements important to cancer research and treatment.

From Illumina, Inc. 3 Nov 2010

GenMark receives non-exclusive license to Innogenetics' HCV genotyping patent estate

GenMark Diagnostics, Inc. a provider of automated, multiplex molecular diagnostic testing systems, announced today that it has acquired a non-exclusive license to Innogenetics' Hepatitis C Virus (HCV) genotyping patent estate for the United States.

3 Nov 2010

International Congress at Spain highlights advances in neuroimmunological disease treatment

The complexity of the immune system and nervous system turn Neuroimmunology into one of the most exciting fields of modern biomedicine. Between October 26th and 30th takes place in Sitges (Barcelona, Spain) the X International Congress of Neuroimmunology of the International Society of Neuroimmunology.

29 Oct 2010

IntegraGen to open subsidiary in Cambridge, Massachusetts

IntegraGen, Inc., a French biotechnology company dedicated to gene discovery and the development of molecular diagnostic products and services, announced today that it is expanding its operations by opening a U.S. subsidiary headquartered in Cambridge, Massachusetts that will support the company's clinical research initiatives focused on the early identification of children at risk of autism. IntegraGen will open the new office on November 1, 2010.

28 Oct 2010

1000 Genomes Project publishes comprehensive map of genetic variations in Nature journal

Small genetic differences between individuals help explain why some people have a higher risk than others for developing illnesses such as diabetes or cancer. Today in the journal Nature, the 1000 Genomes Project, an international public-private consortium, published the most comprehensive map of these genetic differences, called variations, estimated to contain approximately 95 percent of the genetic variation of any person on Earth.

28 Oct 2010

Golden Helix accelerates copy number variation detection methodology

Golden Helix, Inc., today announced the incorporation of technologies that will greatly accelerate genetic research. By enabling the company's SNP & Variation Suite software to run on off-the-shelf video graphics cards, or GPUs, operations that took hours or days can now be completed in a fraction of the time - and without the need for expensive compute clusters or resorting to cloud-based computing. This novel ability will dramatically accelerate many forms of computationally expensive genetic analyses, including that of next generation sequencing data.

27 Oct 2010

S.A.N.E. Vax requests temporary suspension of Gardasil sales as cervical cancer preventive

In a letter addressed to Dr. Margaret Hamburg, the FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc. stated her research team has revealed the fact that in November 2001 the VRBPAC (Vaccines and Related Biological Products Advisory Committee) mistakenly allowed the vaccine manufacturer to use "CIN 2/3, AIS, or cervical cancer; i.e. CIN 2/3 or worse by histology- with virology to determine the associated HPV type- as the primary endpoint in the evaluation of a vaccine to prevent cervical cancer."

25 Oct 2010

454 Life Sciences enters co-promotional agreement with Fluidigm

454 Life Sciences, a Roche Company, and Fluidigm Corporation announced today that they have entered a worldwide co-promotional agreement for the companies' complementary amplicon sample preparation and high-throughput sequencing platforms.

20 Oct 2010

Journal of Clinical Oncology publishes IPI-504 Phase 2 study results

Infinity Pharmaceuticals, Inc. announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.

15 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

RDI launches HIV-TRePS system to predict patients’ response to HIV drugs

A ground-breaking system for predicting how individual patients with HIV and AIDS will respond to different drugs is launched today by RDI, a UK-based not-for-profit research group. The experimental system, called the HIV Treatment Response Prediction System (HIV-TRePS), is available free of charge over the Internet and helps physicians select the best treatment for their patients.

6 Oct 2010

NIH grants Akonni $3M for development of multi-drug resistant/extensively drug-resistant genotyping test

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated genetic testing devices for complex infectious and human diseases, today announced receipt of a nearly $3 million Challenge Grant from the National Institutes of Health (NIH), a new program made possible under the American Recovery and Reinvestment Act (ARRA).

29 Sep 2010